Scientific Program - Epilepsy

Print
Please see below the CONy Scientific Program. Please click on the appropriate section (ordered by ABC) to view the relevant program. Please note that the program and timing is subject to change. To view the program timetable, please click here
 
 
Section Heads: Joanna Jedrzejczak, Poland & Michael Sperling, USA
SATURDAY, MARCH 24, 2018
Hall A
07:00-08:00
E-Poster Presentations
   
08:00-09:50 SESSION 21: EPILEPSY: DIAGNOSIS
  Chairs: Jerzy Majkowski, Poland & Eva Andermann, Canada
08:00-08:55
Can psychogenic seizures be reliably diagnosed just by observing behavior or should continuous EEG always be required?
Capsule:
Are the behaviors of psychogenic seizures sufficiently well understood such that the diagnosis can be made with a high degree of confidence based solely on behavioral manifestations? Given the expense and limited availability of video-EEG monitoring, and the widespread availability of video technology (through smartphones and other means), can video criteria be designated sufficient to diagnose psychogenic seizures?
08:00-08:10 Host: Joanna Jedrzejczak, Poland
08:10-08:25
Pro: Manjari Triapathi, India
08:25-08:40 Con: Ettore Beghi, Italy
08:40-08:55 Discussion and Rebuttals
   
08:55-09:50
Can we rely upon fMRI to localize verbal memory when planning epilepsy surgery?
Capsule: The Wada test has been used to assess risk of memory deficit when temporal lobe resection is planned to treat epilepsy. However, this test is semi-invasive and poses risk, and questions have been raised regarding its validity. fMRI techniques have significantly advanced in the past decade and are widely used to define hemisphere dominance for language. Has it reached the stage where it can be used to identify areas responsible for long-term memory so that Wada may become obsolete?
08:55-09:05 Host: Manjari Tripathi, India
09:05-09:20 Pro: William Theodore, USA
09:20-09:35 Con: Ilan Blatt, Israel
09:35-09:50 Discussion and Rebuttals
   
09:50-10:10 Coffee Break
   
10:10-12:05 SESSION 22: EPILEPSY - THERAPY AND MANAGEMENT
  Chair: Stanislaw Jerzy Czuczwar, Poland & Andrij Dubenko, Ukraine
10:10-11:10
When using combination antiepileptic drug therapy (AED), should we preferentially prescribe drugs with different mechanisms of action, or is the mechanism of action irrelevant to outcome?
Capsule: AEDs have different mechanisms of action. For example, they may alter sodium channel conductance, affect GABA receptors, synaptic vesicle proteins, AMPA receptors, etc. Does the mechanism matter – should we modulate neuronal firing by targeting multiple mechanisms, or does this not matter when considering seizure control?
10:10-10:20
Host: Alla Guekht, Russia
10:20-10:35 Pro: Martin Brodie, UK
10:35-10:50 Con: Martin Holtkamp, Germany
10:50-11:10 Discussion and Rebuttals
   
11:10-11:40
Lecture: Drug Therapy for epilepsy in the elderly: Elinor Ben Menachem, Sweden
Capsule:
What are the special considerations that should be considered when treating elderly individuals with epilepsy? Are there differences in sensitivity to medication, side effect, and efficacy? Do we really know?
11:40-12:10
Case Studies: Michael Sperling, USA
Panelists: Manuel Toledo, Spain, Joanna Jedrzejczak, Poland,
Miri Neufeld, Israel , Thanos Covanis, Greece, Nandan Yardi, India
   
12:10-13:10 Industry Sponsored Symposium (Not for CME) – Hall A
   
13:10-13:55 Lunch Break
   
13:55-15:55
SESSION 23: EPILEPSY: TREATMENT ISSUES
  Chair: Ewa NagaƄska, Poland & Mira Rakacolli, Albania
13:55-14:55 Is there an advantage to continue trying new AED indefinitely in refractory patients?
Capsule: Once pharmacoresistance is demonstrated, new drugs are highly unlikely to produce sustained seizure relief. However, might a new drug convey other advantages or do the potential adverse effects negate any benefit? Are there subsets of patients for whom new drug trials might help?
13:55-14:05
Host: Michael Sperling, USA
14:05-14:20 Pro: Martin Brodie, UK
14:20-14:35 Con: Elinor Ben Menachem, Sweden
14:35-14:55 Discussion and Rebuttals
 
14:55-15:55 Do AED increase the risk of depression or suicidality?
Capsule: People with epilepsy have increased rates of depression and suicide, and one FDA study raised possibility that drugs can increase the risk of suicide. Do drugs really increase risk of depression and suicide, and if so, which agents?
14:55-15:05
Host: Martin Holtkamp, Germany
15:05-15:20 Pro: Ilan Blatt, Israel
15:20-15:35 Con: Alla Guekht, Russia
15:35-15:55 Discussion and Rebuttals
17:00-17:15
Coffee Break
   
16:15-17:40 SESSION 24: EPILEPSY : VAGAL NERVE STIMULATION (VNS) CASE STUDIES
  Chairs: Andrezj Rysz, Poland & Tatyana Litovchenko, Ukraine
16:15-17:10 Should we preferentially use vagus nerve stimulation (VNS) early in patients with both seizures and depression?
Capsule:
VNS has been approved for both psychiatric and epilepsy indications. There is significant co-morbidity of these conditions. VNS be considered as a therapy for patients with both conditions and used early in the course of illness?
16:15-16:25
Host: Zeljka Petelin Gadze, Croatia
16:25-16:40
Pro: Michael Sperling, USA
16:40-16:55 Con: Ivan Rektor, Czech Republic
16:55-17:10 Discussion and rebuttals
   
17:10-19:00
Case Studies: Michael Sperling, USA
Panelists: Manuel Toledo, Spain, Joanna Jedrzejczak, Poland,
Miri Neufeld, Israel , Thanos Covanis, Greece, Nandan Yardi, India